These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 16934924)
1. Effect of glatiramer acetate (Copaxone) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis: a longitudinal study. Blanco Y; Moral EA; Costa M; Gómez-Choco M; Torres-Peraza JF; Alonso-Magdalena L; Alberch J; Jaraquemada D; Arbizu T; Graus F; Saiz A Neurosci Lett; 2006 Oct; 406(3):270-5. PubMed ID: 16934924 [TBL] [Abstract][Full Text] [Related]
2. Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins. Sarchielli P; Zaffaroni M; Floridi A; Greco L; Candeliere A; Mattioni A; Tenaglia S; Di Filippo M; Calabresi P Mult Scler; 2007 Apr; 13(3):313-31. PubMed ID: 17439900 [TBL] [Abstract][Full Text] [Related]
3. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Aharoni R; Kayhan B; Eilam R; Sela M; Arnon R Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14157-62. PubMed ID: 14614135 [TBL] [Abstract][Full Text] [Related]
4. Failure of glatiramer acetate to modify the peripheral T cell repertoire of relapsing-remitting multiple sclerosis patients. Berthelot L; Miqueu P; Pettré S; Guillet M; Moynard J; Wiertlewski S; Lefrère F; Brouard S; Soulillou JP; Laplaud DA Clin Immunol; 2010 Apr; 135(1):33-42. PubMed ID: 20116333 [TBL] [Abstract][Full Text] [Related]
6. Immunological assay for assessing the efficacy of glatiramer acetate (Copaxone) in multiple sclerosis. A pilot study. Farina C; Wagenpfeil S; Hohlfeld R J Neurol; 2002 Nov; 249(11):1587-92. PubMed ID: 12420101 [TBL] [Abstract][Full Text] [Related]
7. Long-term favorable response to interferon beta-1b is linked to cytokine deviation toward the Th2 and Tc2 sides in Japanese patients with multiple sclerosis. Mei FJ; Osoegawa M; Ochi H; Minohara M; Nan S; Murai H; Ishizu T; Taniwaki T; Kira J J Neurol Sci; 2006 Jul; 246(1-2):71-7. PubMed ID: 16581087 [TBL] [Abstract][Full Text] [Related]
8. Glatiramer acetate: mechanisms of action in multiple sclerosis. Ziemssen T; Schrempf W Int Rev Neurobiol; 2007; 79():537-70. PubMed ID: 17531858 [TBL] [Abstract][Full Text] [Related]
9. Changes of percentages in immune cells phenotypes and cytokines production during two-year IFN-beta-1a treatment in multiple sclerosis patients. Mirowska D; Skierski J; Paź A; Koronkiewicz M; Zaborski J; Kruszewska J; Członkowski A; Członkowska A J Neurol; 2003 Oct; 250(10):1229-36. PubMed ID: 14586608 [TBL] [Abstract][Full Text] [Related]
10. Renewal of the T-cell compartment in multiple sclerosis patients treated with glatiramer acetate. Chiarini M; Sottini A; Ghidini C; Zanotti C; Serana F; Rottoli M; Zaffaroni M; Bergamaschi R; Cordioli C; Capra R; Imberti L Mult Scler; 2010 Feb; 16(2):218-27. PubMed ID: 20007428 [TBL] [Abstract][Full Text] [Related]
11. Effect of glatiramer acetate (Copaxone) on CD4+CD25high T regulatory cells and their IL-10 production in multiple sclerosis. Putheti P; Soderstrom M; Link H; Huang YM J Neuroimmunol; 2003 Nov; 144(1-2):125-31. PubMed ID: 14597106 [TBL] [Abstract][Full Text] [Related]
12. Clinical response to glatiramer acetate correlates with modulation of IFN-gamma and IL-4 expression in multiple sclerosis. Valenzuela RM; Costello K; Chen M; Said A; Johnson KP; Dhib-Jalbut S Mult Scler; 2007 Jul; 13(6):754-62. PubMed ID: 17613604 [TBL] [Abstract][Full Text] [Related]
13. Beneficial effect of glatiramer acetate (Copaxone) on immune modulation of experimental hepatic fibrosis. Horani A; Muhanna N; Pappo O; Melhem A; Alvarez CE; Doron S; Wehbi W; Dimitrios K; Friedman SL; Safadi R Am J Physiol Gastrointest Liver Physiol; 2007 Feb; 292(2):G628-38. PubMed ID: 17038628 [TBL] [Abstract][Full Text] [Related]
14. Effect of immunomodulatory treatment of multiple sclerosis on lymphocyte surface immunomarkers. Michałowska-Wender G; Losy J; Wender M; Januszkiewicz-Lewandowska D; Nowak J Pol J Pharmacol; 2003; 55(5):877-80. PubMed ID: 14704481 [TBL] [Abstract][Full Text] [Related]
15. Oral glatiramer acetate in experimental autoimmune encephalomyelitis: clinical and immunological studies. Teitelbaum D; Aharoni R; Klinger E; Kreitman R; Raymond E; Malley A; Shofti R; Sela M; Arnon R Ann N Y Acad Sci; 2004 Dec; 1029():239-49. PubMed ID: 15681762 [TBL] [Abstract][Full Text] [Related]
16. Glatiramer acetate-specific human CD8(+) T cells: increased IL-4 production in multiple sclerosis is reduced by glatiramer acetate treatment. Dressel A; Vogelgesang A; Brinkmeier H; Mäder M; Weber F J Neuroimmunol; 2006 Dec; 181(1-2):133-40. PubMed ID: 17084909 [TBL] [Abstract][Full Text] [Related]
17. Clinical and immunologic effects of T-activin therapy in early stage melanoma patients. Stanojević-Bakić N; Milosević D; Vucković-Dekić L; Sasić M; Marković L Neoplasma; 1996; 43(4):245-52. PubMed ID: 8931749 [TBL] [Abstract][Full Text] [Related]
18. [Changes in lymphocyte subsets s and treatment with beta interferon in active multiple sclerosis]. Gata JM; García-Moreno JM; Dinca L; Sánchez-Margalet V; Navarro G; Izquierdo G Rev Neurol; 1998 Dec; 27(160):939-42. PubMed ID: 9951008 [TBL] [Abstract][Full Text] [Related]
19. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis. Hamamcioglu K; Reder AT Mult Scler; 2007 May; 13(4):459-70. PubMed ID: 17463069 [TBL] [Abstract][Full Text] [Related]
20. Dendritic cell, monocyte and T cell activation and response to glatiramer acetate in multiple sclerosis. Sellebjerg F; Hesse D; Limborg S; Lund H; Søndergaard HB; Krakauer M; Sørensen PS Mult Scler; 2013 Feb; 19(2):179-87. PubMed ID: 22653658 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]